name,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Feb '25),Est. Status,vh,vl,HeavySequence(ifbispec),LightSequence(ifbispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes,Genetics (Bispecifics delimited with semicolon),Alternative Therapeutic Names
Caplacizumab,Nanobody,na,na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS,na,na,na,7a6o:B/7eow:B,None,None,2011,2012,VWF,Ablynx,Thrombotic thrombocytopenic purpura,na,Thrombosis,Nanobody Technology,,Humanised,ALX-0081;ALX0081;ALX-0681;ALX0681
